A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective
Open Access
- 1 July 2021
- journal article
- research article
- Published by Informa UK Limited in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 3147-3160
- https://doi.org/10.2147/dmso.s284855
Abstract
Background: Obesity is a disease associated with high direct medical costs and high indirect costs resulting from productivity loss. The high prevalence of obesity generates the need for payers to identify cost-effective weight loss approaches. Among various weight management techniques, the OPTI (Optifast®) program is a clinically recognised total meal replacement diet that can lead to significant weight loss and reduction in complications. This study’s objective is to assess OPTI program’s cost-effectiveness in Switzerland in comparison to “no intervention” and pharmacotherapy. Methods: An event-driven decision-analytic model was used to estimate the payer’s cost savings through the reimbursement of OPTI program over a 1-year period as well as a lifetime in Switzerland. The analysis was performed on a broad population of people with obesity with a body mass index (BMI) higher than 30 kg/m2 following the OPTI program vs two comparators (liraglutide and “no intervention”). The model incorporated a higher risk of complications due to an increased BMI and their related healthcare costs. Data sources included published literature, clinical trials, official Swiss price/tariff lists and national population statistics. The primary perspective was that of a Swiss payer. Scenario analyses – for example, for patients with existing complications (such as myocardial infarction, stroke, type 2 diabetes mellitus) or severe obesity – were conducted to test the robustness of the results. Results: The OPTI program results in cost savings of CHF 20,886 (€ 18,724) and CHF 15,382 (€ 13,790) per person compared with “no intervention” and liraglutide 3 mg, respectively. In addition, OPTI program led to 1.133 and 0.734 quality-adjusted life years (QALYs) gained respectively against its comparators. Scenario analyses showed similar outcomes with cost savings and QALYs gained. Conclusion: OPTI program is a dominant strategy compared to “no intervention” and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.Keywords
This publication has 60 references indexed in Scilit:
- Economic costs of overweight and obesityBest Practice & Research Clinical Endocrinology & Metabolism, 2013
- Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life—a prospective studyInternational Journal of Obesity, 2011
- Cost-Effectiveness of Bariatric Surgery for Severely Obese Adults With DiabetesDiabetes Care, 2010
- Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell CarcinomaValue in Health, 2010
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysisBMC Public Health, 2009
- Health state utilities for non small cell lung cancerHealth and Quality of Life Outcomes, 2008
- Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluationInternational Journal of Obesity, 2003
- Estimating the Effect of Changes in Body Mass Index on Health State PreferencesPharmacoEconomics, 2002
- The Swedish Obese Subjects (SOS) study—rationale and resultsInternational Journal of Obesity, 2001
- Randomized Trial of Diet and Gastroplasty Compared with Diet Alone in Morbid ObesityNew England Journal of Medicine, 1984